Charles Schwab Investment Management Inc. Sells 9,163 Shares of LeMaitre Vascular, Inc. $LMAT

Charles Schwab Investment Management Inc. trimmed its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 4.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 186,589 shares of the medical instruments supplier’s stock after selling 9,163 shares during the period. Charles Schwab Investment Management Inc. owned about 0.83% of LeMaitre Vascular worth $15,655,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Blueshift Asset Management LLC bought a new stake in shares of LeMaitre Vascular during the 1st quarter worth $232,000. US Bancorp DE raised its stake in shares of LeMaitre Vascular by 36.0% during the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 368 shares during the period. Vestcor Inc raised its stake in shares of LeMaitre Vascular by 108.0% during the 1st quarter. Vestcor Inc now owns 3,079 shares of the medical instruments supplier’s stock worth $258,000 after purchasing an additional 1,599 shares during the period. Federated Hermes Inc. raised its stake in shares of LeMaitre Vascular by 1.3% during the 1st quarter. Federated Hermes Inc. now owns 39,504 shares of the medical instruments supplier’s stock worth $3,314,000 after purchasing an additional 518 shares during the period. Finally, Cetera Investment Advisers raised its stake in shares of LeMaitre Vascular by 209.6% during the 1st quarter. Cetera Investment Advisers now owns 8,522 shares of the medical instruments supplier’s stock worth $715,000 after purchasing an additional 5,769 shares during the period. 84.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

LMAT has been the topic of a number of recent analyst reports. Cantor Fitzgerald lifted their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Barrington Research raised LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 price objective for the company in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, LeMaitre Vascular has a consensus rating of “Hold” and an average target price of $97.60.

Insiders Place Their Bets

In related news, Director David B. Roberts sold 10,815 shares of the business’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $92.39, for a total value of $999,197.85. Following the completion of the sale, the director owned 17,976 shares in the company, valued at $1,660,802.64. The trade was a 37.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO George W. Lemaitre sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total value of $9,351,000.00. Following the completion of the sale, the chief executive officer owned 1,727,003 shares of the company’s stock, valued at $161,492,050.53. The trade was a 5.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 120,815 shares of company stock worth $11,280,206 over the last three months. Company insiders own 9.50% of the company’s stock.

LeMaitre Vascular Trading Up 4.0%

Shares of LMAT opened at $100.33 on Friday. The business has a 50-day moving average of $85.98 and a 200 day moving average of $86.49. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The firm has a market cap of $2.27 billion, a P/E ratio of 48.70, a price-to-earnings-growth ratio of 2.48 and a beta of 0.79. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The company had revenue of $63.15 million during the quarter, compared to analyst estimates of $62.48 million. During the same quarter last year, the firm posted $0.52 EPS. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. LeMaitre Vascular’s payout ratio is presently 38.83%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.